OUR NEWS AND EVENTS

Merck is active in dealmaking worldwide.

Come meet us at an upcoming event.

January 9-11, 2012   Biotech 2012
San Francisco, California, USA
January 31-February 1, 2012   BIO Asia Partnering Conference
Osaka, Japan
January 31-February 2, 2012   Worldwide Business Research BioBusiness
London, United Kingdom
February 1-2, 2012   BIOCOM Second Annual Global Life Science Partnering Conference
La Jolla, California, USA
February 26-28, 2012   BioPartnering North America
Vancouver, British Columbia, Canada
March 5-7, 2012   BioNetwork East
Miami Beach, Florida, USA
March 14-17, 2012   AUTM 2011 Annual Meeting
Anaheim, California, USA
March 14-21, 2012   BIO-Europe Spring
Amsterdam, The Netherlands

Read about our recent partnerships.

Dec 21, 2011   Exelixis Licenses PI3K-Delta Program to Merck
Dec 15, 2011   Merck Announces Initiation of Clinical Development Collaboration with Roche To Evaluate Investigational Combination Regimens for the Treatment of Chronic Hepatitis C Genotype 1 Infection
Dec 13, 2011   Mochida announces License Agreement with Merck
Dec 12, 2011   EnWave Signs Research Evaluation Agreement with Merck
Dec 9, 2011   Ezose Sciences in New Agreement with Merck to Advance Glycan Biomarker Discovery in Diabetes
Dec 8, 2011   NanoBio® to Collaborate in Research Effort for Respiratory Syncytial Virus Vaccine With Merck
Nov 14, 2011   Bend Research Signs Technology Licensing Agreement with Merck
Sep 13, 2011   Merck and BGI Establish Strategic Collaboration focused on Biomarkers and Genomic Technologies
Aug 29, 2011   Zymeworks Inc. Announces Collaboration with Merck to Develop Bi-specific Antibody Therapeutics
Aug 3, 2011   Merck and Serum Institute Announce Collaboration to Develop and Expand Global Access to Pneumococcal Conjugate Vaccine (PCV)
Aug 1, 2011   AbD Serotec and Merck Sign License Agreement for Use of HuCAL GOLD in Vaccine Research
Jul 26, 2011   Merck to Acquire Rights to Vernakalant i.v. in Canada, Mexico and the United States from Astellas
Jul 21, 2011   Merck and Simcere Sign Agreement to Establish Pioneering China Joint Venture
Jul 20, 2011   Merck and Roche Expand Agreement in Fight Against Chronic Hepatitis C
Jul 11, 2011   Merck to Participate in New Research Efforts to Eradicate HIV
Jun 7, 2011   Roche and Merck Collaborate to Develop Diagnostic Tests for Merck's Investigational Cancer Therapies
May 2, 2011   BeiGene receives Investment from Merck
Apr 11, 2011   Merck & Co., Inc., and Sun Pharma Establish Joint Venture to Develop and Commercialize Novel Formulations and Combinations of Medicines in Emerging Markets
Apr 5, 2011   Merck to Acquire Inspire Pharmaceuticals, Inc.
Mar 3, 2011   Lycera Announces Research Collaboration with Merck to Discover, Develop and Commercialize Drugs for Autoimmune Diseases
Jan 12, 2011   Merck and PAREXEL Form Strategic Alliance Focused on Clinical Development of Biosimilar Candidates
Dec 14, 2010   BioPontis Alliance announces agreement with Merck in translational drug research
Dec 2, 2010   Merck to Acquire SmartCells, Inc.
Oct 13, 2010   Weight Watchers and Merck Collaborate to Help Physicians Fight Obesity Through Lifestyle Management Approach
Oct 12, 2010   Lundbeck and Merck Sign Exclusive Commercialization Agreement for SYCREST® (asenapine) Sublingual Tablets in All Markets Outside of the United States, China and Japan
Oct 4, 2010   BioRelix Enters Antibacterial Collaboration with Merck
Sep 30, 2010   ThromboGenics Signs Deal with MSD for Long-Term Commercial Supply of Microplasmin
Sep 15, 2010   Merck and BGI Sign Statement of Intent to Collaborate to Advance the Application of Genomics in Medicine
Sep 15, 2010   NicOx and Merck to Broaden Scope of
License Agreement
Aug 11, 2010   Alectos Therapeutics Announces Collaboration with Merck to Develop Drugs for Alzheimer's Disease
Jul 27, 2010   Sinopharm and Merck Sign Statement of Mutual Intent
June 3, 2010   Merck Announces Launch of Pioneering Collaborative Cancer Trials Network at 2010 American Society of Clinical
Oncology Meeting
May 17, 2010   Elexopharm Enters into Cardiovascular Collaboration with Merck & Co., Inc.
Apr 26, 2010   Nycomed and Merck & Co., Inc., announce commercialization agreements for Daxas® in Europe and Canada
March 30, 2010   Sage Bionetworks Announces Integrative Genomics Research Program with Merck & Co., Inc.
Feb 23, 2010   Lilly, Merck, and Pfizer Join Forces to Accelerate Research and Improve Treatment of Lung and Gastric Cancers in Asia
Feb 17, 2010   Roche Collaborates with Merck on Developmental Test for Cancer-Related Gene Mutation
Feb 17, 2010   BG Medicine Collaborates with Merck on Development of Blood Test Related to Lipid Disorders
Feb 8, 2010   AnaptysBio Announces Strategic Collaboration with
Merck & Co., Inc.
Jan 26, 2010   Envoy Enters Diabetes and Obesity Collaboration with
Merck & Co., Inc.
January 9, 2012   Idera Pharmaceuticals Announces Selection of Toll-like Receptor Agonist Candidates for Evaluation as Vaccine Adjuvants by Merck
December 21, 2011   Lycera Achieves First Milestone in Merck Research Collaboration
December 20, 2011   Orchid’s Drug Discovery Research Initiative with Merck Advances
December 13, 2011   Massbiologics Receives Milestone Payment From Merck for Advancement of Monoclonal Antibody Candidate Into Phase III Study
August 18, 2011   Merck and ARIAD Announce European Medicines Agency Accepts Marketing Authorization Application for Ridaforolimus, Investigational mTOR Inhibitor
April 18, 2011   Quest Diagnostics Launches Hepatitis C Virus Therapy Test Based on IL28B Gene Variants
Feb 18, 2011   Merck Canada Invests $6.8 Million in Research in Quebec
Jan 18, 2011   Ariad Announces Oral Ridaforolimus Achieved Primary Endpoint of Improved Progression-Free Survival in Patients With Metastatic Soft-Tissue or Bone Sarcomas in the Phase 3 Succeed Trial
Jan 4, 2011   Anaptysbio Receives Milestone Payment From Merck for Successful Delivery of Candidate Antibodies for Therapeutic Use
Dec 15, 2010   Envoy Achieves Milestone in Diabetes and Obesity Alliance
with Merck
Dec 3, 2010   Ligand Announces Presentation of Data from Multiple Studies of Dinaciclib by its Partner Merck at the ASH Annual Meeting
Nov. 18, 2010   Intercell Announces Initial Results of Phase II Clinical Trial Evaluating V710, an Investigational Staphylococcus Aureus Vaccine, in Patients With End-Stage Renal Disease
Nov 1, 2010   Depomed Receives $2.5 Million Milestone Payment Under Merck License Agreement
Oct 25, 2010   Ariad Announces Interim Results From Randomized Phase 2 Trial of Oral Ridaforolimus in Advanced Endometrial Cancer
Oct 18, 2010   New Data on Odanacatib, Merck's Investigational Cathepsin-K Inhibitor for Osteoporosis, Presented at American Society for Bone and Mineral Research Annual Meeting
Sep 14, 2010   SCYNEXIS Announces Presentations of Data from Anti-fungal Drug Candidate at the 50th ICAAC Meeting
July 27, 2010   Merck Grants License to LabCorp for Development of Test To Potentially Identify Patients Likely to Respond to Hepatitis C Therapy
June 21, 2010   Merck and Codexis Honored with Presidential Green Chemistry Challenge Award for Novel Process for
Sitagliptin Synthesis
June 5, 2010   AVEO Pharmaceuticals Initiates Phase 2 Clinical Trial Evaluating SCH 900105 (AV-299) in Non-Small Cell
Lung Cancer
May 14, 2010   Merck and Cardiome Announce Phase III Study Results Comparing Investigational Compound BRINAVESS™ (Vernakalant) Intravenous to Amiodarone Injection in Conversion of Atrial Fibrillation to Normal Sinus Rhythm
May 5, 2010   Merck Acquires Development and Commercialization Rights to Investigational mTOR Inhibitor Ridaforolimus from ARIAD Pharmaceuticals, Inc.
Apr 21, 2010   Merck Obtains Exclusive Rights to Market and Distribute MassBiologics' Tetanus-Diphtheria (Td) Vaccine in the U.S.
Mar 15, 2010   Portola Pharmaceuticals and Merck Announce that Phase 2 Study Showed Investigational Factor Xa Inhibitor, Betrixaban, Reduced Incidence of Bleeding Compared to Warfarin in Patients with Atrial Fibrillation
Jan 15, 2010   Galapagos Achieves Milestones in Strategic Alliances with Merck & Co., Inc.

At Merck, flexibility, innovation and creativity are at the heart of the way we work with partners around the world.

Our Licensing team works with partners to advance their science through drug discovery and development collaborations and licensing agreements that are mutually beneficial.

Our Commercial Partnerships team pursues business opportunities with partners to jointly deliver their products and ours to the marketplace.

Pamela Demain, MBA, CLP, Executive Director, Corporate Licensing
"We welcome partnerships at all stages of discovery and development. As our partner, you will find that Merck is highly committed to ensuring the success of the opportunity through high prioritization, close collaboration, and the excellence of our research, development, marketing, and sales organizations."
Pamela Demain, MBA, CLP
Executive Director, Corporate Licensing
TRUSTe - Click to Verify   This Web This Web Accessibility icon serves as a link to download eSSENTIAL Accessibility assistive technology software for individuals with physical disabilities. It is being featured as part of a Disability Community Involvement initiative that reflects our commitment to Diversity, Inclusion,Corporate Citizenship and Social Responsibility.